Kerala Ayurveda Past Earnings Performance
Past criteria checks 2/6
Kerala Ayurveda's earnings have been declining at an average annual rate of -21.3%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 12% per year. Kerala Ayurveda's return on equity is 9%, and it has net margins of 2.4%.
Key information
-21.3%
Earnings growth rate
-23.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 12.0% |
| Return on equity | 9.0% |
| Net Margin | 2.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Kerala Ayurveda makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,179 | 29 | 484 | 0 |
| 30 Jun 24 | 1,070 | -8 | 368 | 0 |
| 31 Mar 24 | 1,082 | -15 | 432 | 0 |
| 31 Dec 23 | 1,066 | -14 | 413 | 0 |
| 30 Sep 23 | 1,007 | -14 | 395 | 0 |
| 30 Jun 23 | 984 | -4 | 372 | 0 |
| 31 Mar 23 | 936 | -9 | 364 | 0 |
| 31 Dec 22 | 916 | -4 | 357 | 0 |
| 30 Sep 22 | 869 | 28 | 299 | 0 |
| 30 Jun 22 | 788 | 12 | 233 | 0 |
| 31 Mar 22 | 804 | 24 | 282 | 0 |
| 31 Dec 21 | 757 | -14 | 292 | 0 |
| 30 Sep 21 | 726 | -35 | 288 | 0 |
| 30 Jun 21 | 650 | -43 | 239 | 0 |
| 31 Mar 21 | 621 | -48 | 265 | 0 |
| 31 Dec 20 | 645 | -16 | 270 | 0 |
| 30 Sep 20 | 668 | -7 | 272 | 0 |
| 30 Jun 20 | 674 | 25 | 230 | 0 |
| 31 Mar 20 | 768 | 39 | 300 | 0 |
| 31 Dec 19 | 726 | 47 | 272 | 0 |
| 30 Sep 19 | 692 | 47 | 266 | 0 |
| 30 Jun 19 | 610 | 33 | 216 | 0 |
| 31 Mar 19 | 622 | 24 | 249 | 0 |
| 31 Mar 18 | 589 | 28 | 217 | 0 |
| 31 Mar 17 | 504 | 31 | 188 | 0 |
| 31 Mar 16 | 459 | 27 | 168 | 0 |
| 31 Mar 15 | 390 | 24 | 149 | 0 |
| 31 Mar 14 | 349 | 7 | 219 | 0 |
Quality Earnings: 530163 has high quality earnings.
Growing Profit Margin: 530163 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 530163's earnings have declined by 21.3% per year over the past 5 years.
Accelerating Growth: 530163 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 530163 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20%).
Return on Equity
High ROE: 530163's Return on Equity (9%) is considered low.